
NVO
37.83 USD
-2.33%
Today
-2.33%
1D
Market is closed
Sun
Closed
Mon
3:00 AM ~ 12:00 PM
Tue
12:00 AM ~ 12:00 PM
Wed
12:00 AM ~ 12:00 PM
Thu
12:00 AM ~ 12:00 PM
Fri
12:00 AM ~ 11:00 PM
Sat
Closed
Information
Name
Novo Nordisk A/S Leveraged
Currency
USD
Core Leverage
1:2
Plus Leverage
1:2
Max Leverage
1:10
Overnight Fees Buy (Core Leverage)
-0.0190%
Overnight Fees Sell (Core Leverage)
0.0024%
Overnight Fees Buy (Plus Leverage)
-0.0190%
Overnight Fees Sell (Plus Leverage)
0.0024%
Overnight Fees Buy (Max Leverage)
-0.0190%
Overnight Fees Sell (Max Leverage)
0.0024%
Market Cap
183.52B
Avg Daily Volume
12.36M
52 Week High
64.16 USD
52 Week Low
35.12 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01900% | $(0.190) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Top News
CVSCare
+1.33%
EliLilly
+0.18%
NovoNordisk
-2.33%
CVS Sees a Possible Break-Even Point for GLP-1s
tradingview.com
5d ago

CVSCare
+1.33%
EliLilly
+0.18%
NovoNordisk
-2.33%
CVS white paper aims to pressure drugmakers to lower GLP-1 prices
finance.yahoo.com
5d ago

EliLilly
+0.18%
NovoNordisk
-2.33%
Pfizer
-0.29%
AmgenInc
-0.27%
RoperTechn
+1.77%
Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035
finance.yahoo.com
5d ago

Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.

